PYC Physiomics Plc
Physiomics Plc engages in the provision of consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. It also develops technology for use in the field of personalized medicine. The company was incorporated in 2001 and is based in Oxford, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Physiomics (LON: PYC)
›
Physiomics (LON: PYC) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 11 employees.
The shares were at 0.4150 GBp on 19 November 2026, down 1.2% over 52 weeks. Its 52-week range is 0.2530 GBp to 0.8000 GBp: the price is 48.1% below the high and 64.0% above the low.
Its market capitalisation is 1.94M GBP.
Physiomics reports return on equity of -133.0%, an operating margin of -65.0% and revenue up 9.8% year over year.
It holds more cash than debt, a net cash position of 418.63K GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.